Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04685616

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR)

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Sponsor: Australasian Leukaemia and Lymphoma Group

Conditions Hodgkin Lymphoma

Interventions Bleomycin Brentuximab vedotin Dacarbazine Doxorubicin Haematopoietic growth factor Involved site radiotherapy Vinblastine

Updated 23 times since 2021 Last updated: Feb 16, 2026 Started: Apr 14, 2022 Primary completion: Sep 30, 2030 Completion: Sep 30, 2032

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hodgkin Lymphoma and is currently actively recruiting participants. Australasian Leukaemia and Lymphoma Group leads this study, which shows 23 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

23 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Nov 2025 — Feb 2026 [monthly]

Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE3

▶ Show 18 earlier versions

May 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Apr 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jun 2024 [monthly]

Recruiting PHASE3
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Jan 2023 — May 2023 [monthly]

Recruiting PHASE3
Sep 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE3
May 2022 — Jun 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2021 — May 2022 [monthly]

Not Yet Recruiting PHASE3
Jan 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Australasian Leukaemia and Lymphoma Group
Canadian Cancer Trials Group
European Organisation for Research and Treatment of Cancer - EORTC
Seagen Inc.
Takeda
University College, London
University of Miami

Data source: University College, London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Aberdeen, United Kingdom , Adelaide, Australia , Amsterdam, Netherlands , Antwerp, Belgium , Auckland, New Zealand , Barcelona, Spain , Birmingham, United Kingdom , Blackpool, United Kingdom , Bodelwyddan, United Kingdom and 52 more locations